COMMUNIQUÉS West-GlobeNewswire

Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
23/02/2024
Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 23, 2024 . Sanofi announces today the filing of its Form 20-F with the U.S. [...]
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2023, contenant le Rapport Financier Annuel, et du « Form 20-F » américain
23/02/2024
Dépôt du Document d’Enregistrement Universel 2023, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Paris, le 23 février 2024 . Sanofi annonce avoir déposé son Document d’Enregistrement Universel [...]
Latest Holistic Approach for those Struggling With Chemical Dependency
23/02/2024
The Ibogaine Research Center is conducting comprehensive research on addiction treatments. The group, headed by David Dardashti, comprises specialists in organizational psychology (Gavriel Dardashti), Data Coordination [...]
Tilray Medical Applauds German Bundestag and Landmark Passage of Medical Cannabis Act in Germany
23/02/2024
New Medical Cannabis Act in Germany Provides Easier Access to Medical Cannabis for Patients Through the MedCanG COLOGNE, Germany and NEUMÜNSTER, Germany, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray [...]
VITAS® Healthcare Continues Its Pathway of Success and Promotes Two Key Operations Executives
23/02/2024
MIAMI, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Two executive leaders at VITAS Healthcare have been promoted to top operational roles. Joel Wherley now serves as president and chief operating officer (COO) and Bryan Wysong as [...]
Curai Health to Expand Access to Care for Individuals Experiencing Homelessness
23/02/2024
LOS ANGELES, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Today, Curai Health , a virtual clinic, announced that it is expanding access to high-quality care for individuals experiencing homelessness. In collaboration with [...]
AVITA Medical to Host Investor Webinar Briefing
23/02/2024
VALENCIA, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin [...]
Strainsforpains Inc. Announces Corporate Update
23/02/2024
NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- (Strainsforpains, Inc.) (OTC Markets: EBYH). Strainsforpains is pleased to announce that it has increased the capacity of its Pennsylvania facility to accommodate the company’ [...]
Curia Appoints Steve Lavezoli as Vice President, Biologics
23/02/2024
ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective [...]
Ceapro Provides Business Update on Progress of Ongoing Development Programs, Technology and Cosmeceutical Base Business
23/02/2024
EDMONTON, Alberta, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), today provided an update on its progress across its current business. On December 14, 2023, the [...]
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity
23/02/2024
Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29 th at 12:00 PM ET THE WOODLANDS, TX, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or [...]
Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update
23/02/2024
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Biodexa Announces Positive Top Line Phase I Clinical Trial Results for Diffuse Midline Glioma and Provides R&D Update Median Overall Survival of 16.5 Months [...]
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
23/02/2024
REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) [...]
Venus Concept Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
23/02/2024
TORONTO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive [...]
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
23/02/2024
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing [...]
Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®
23/02/2024
Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following stem cell transplant with Omisirge ® (omidubicel-onlv) Preliminary [...]
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
23/02/2024
FARMINGTON HILLS, Mich., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small- [...]
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
23/02/2024
Conference call to be held Wednesday, February 28, 2024, at 8:30 AM ET NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Wednesday, [...]
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
23/02/2024
For the first time, patients with alcohol use disorder will receive the company's unique and proprietary psychedelic - MEAI Vancouver, Canada, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND [...]

Pages